Chinese Expert Consensus on Medication Safety in Polypharmacy in Type 2 Diabetics with Chronic Kidney Disease

Abstract

Diabetes is a serious public health problem worldwide. The prevalence of chronic kidney disease (CKD) secondary to type 2 diabetes mellitus (T2DM) is growing with the increase of T2DM prevalence. There is no comprehensive guideline on medication safety in polypharmacy in patients with T2DM-related CKD. This consensus provides guidance on safety issues in polypharmacy for clinical pharmacists and Chinese patients with T2DM-related CKD, and a summary of the information on usage and dosage, and related pharmaceutical characteristics of drugs as well as medication for special populations for supporting clinical medical workers in delivering standardized medication services.

Keywords

• diabetes mellitus, type 2|chronic kidney disease (ckd)|renal insufficiency, chronic|polypharmacy|expert consensus|guideline